

Case Report

Characteristic of Uterine Lipoleiomyoma and Hemangioma by Algorithm of Candidate Biomarkers for Uterine Mesenchymal Tumor

Shoko Nishikawa¹, Takuma Hayashi^{2,3,*}, Yasuaki Amanao¹, Nobuo Yaegashi^{3,4}, Kaoru Abiko¹ and Ikuo Konishi^{1,3,5}

¹ Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan

² Section of Cancer Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan

³ Japan Agency for Medical Research and Development (AMED), Tokyo, Japan

⁴ Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Miyagi, Japan

⁵ Kyoto University School of Medicine, Kyoto, Japan

*Corresponding author: yoyoyo224@hotmail.com; Tel.: +81263372629

Abstract: Background/Aim: In clinical practice, uterine lipoleiomyomas are variants of uterine leiomyomas, often found incidentally, and do not require surgical treatment unless patient's symptomatic. Therefore, these should be clinically differentiated from lesions that need surgical treatment. Conversely, hemangiomas, or blood vessel benign tumors, rarely develop in the uterus; however, many clinical complications such as abdominal pain and excessive vaginal bleeding result from a uterine hemangioma. Hemangiomas can occur at any age and primarily affect pregnant women.

Materials and Methods: The oncological properties of uterine lipoleiomyoma and hemangioma in adults were investigated using molecular pathological examination on tissue excised from patients with uterine leiomyoma. **Results:** Through molecular pathological studies, which included potential biomarkers for uterine mesenchymal tumors, a differential diagnosis was established for this case of mesenchymal tumor. Herein, we report a 54-year-old non-pregnant woman who presented with vaginal bleeding and underwent hysterectomy after detection of a 140 × 100 mm intramural mass diagnosed as a concurrent uterine hemangioma and lipoleiomyoma after molecular histopathologic examinations. **Conclusion:** As far as we know, this case is the first patient of concurrent uterine hemangioma and lipoleiomyoma. Hence, such occurrence of several types of mesenchymal tumors must be considered in the differential diagnosis of patients with abnormal vaginal bleeding.

Keywords: lipoleiomyoma; hemangioma; bleeding; uterine leiomyoma; uterine leiomyosarcoma

1. Introduction

Among all gynecologic tumors, uterine leiomyoma is the most common benign gynecological tumor. The majority of uterine leiomyomas are found in women in their 40s and 50s (1). By age, the incidence of uterine leiomyoma is thought to occur in 20%–30% of women aged 30 years and over and in 70% of women aged 40 years and over (2,3). Women of sexual maturity are the most affected population with clinically relevant uterine leiomyomas. Moreover, the incidence of uterine leiomyoma is significantly lower in women under the age of 18 years (2). Additionally, uterine leiomyoma that was observed before menopause has been shown to shrink after menopause (3). Furthermore, a rapid growth of uterine leiomyomas has been demonstrated in pregnant women and women taking oral contraceptives. Based on these clinical findings, a uterine leiomyoma is thought to be female hormone-dependent (2,3).

In many cases of uterine leiomyomas, spindle-shaped smooth muscle cells proliferate in mutually orthogonal fascicles or whorls. Uterine leiomyoma cell nuclei are uniform and elongated, with round to blunt cell ends. In uterine smooth muscle tumor cell size, there is almost no difference, or the difference is extremely mild. Uterine leiomyomas have

minimal or no increase in chromatin and have very small nucleoli or are nonexistent. Therefore, in uterine leiomyoma, nuclear atypia is absent. Uterine leiomyomas with mixed adipocytes are classified as lipoleiomyoma. Uterine leiomyoma with a conspicuous fatty component is referred to as lipoleiomyoma (3).

Hemangioma, on the contrary, refers to a benign tumor formed by the dilation or proliferation of blood vessels. Medically, hemangiomas depict vascular endothelial cell proliferation, while vascular malformations are not characterized by proliferation. Hemangiomas include infantile hemangiomas and tufted hemangiomas. Vascular malformations include port-wine nevus (simple hemangiomas), cavernous hemangiomas, and arteriovenous malformations. Uterine hemangiomas are rare benign vascular tumors that can cause abnormal vaginal bleeding in different age groups. Patients with these tumors present with menorrhagia or pregnancy-related complications. Magnetic resonance imaging (MRI) is usually utilized for the differential diagnosis between hemangiomas and other diseases; however, only a few studies elucidate on its detection ability. Compared with other imaging tests, MRI has a high-detection capability for uterine hemangiomas, and comprehensive reports on hemangioma reveal the detection rate by MRI. In general, MRI imaging is better at detecting hemangiomas than ultrasound or computed tomography (CT) imaging (4,5). In particular, the detection rate of hemangiomas on T2-weighted imaging is 93%–100% (5,6). Incidental findings of hemangiomas using MRI are often encountered in daily clinical practice, and establishing a correct diagnosis is paramount.

A 53-year-old non-pregnant woman with significant vaginal bleeding presented to our medical facility. An outpatient MRI imaging study revealed a mass measuring 140 × 100 mm, suggestive of uterine lipoleiomyoma. Surgical treatment was performed, and the tissue was sent for pathological examination which revealed a concurrent uterine lipoleiomyoma and hemangioma. We report a case of concurrent uterine lipoleiomyoma and hemangioma. To our knowledge, this is the first case of concurrent uterine hemangioma and intramural leiomyoma. In the differential diagnosis of patients with abnormal vaginal bleeding, it is necessary to consider the possibility of such uterine hemangiomas.

2. Materials and Methods

2.1. Immunohistochemistry (IHC)

Our clinical research group carried out IHC staining for caveolin 1, cyclin B, cyclin E1, large multifunctional peptidase 2/β1i (LMP2/β1i), Ki-67/MIB1, and cluster of differentiation 31 (CD31) using serial human uterine mesenchymal tumor sections obtained from patients with uterine mesenchymal tumor ([Supplementary Material 1](#)). Our clinical research group purchased a monoclonal antibody against cyclin E1 (CCNE1/2460) from Abcam (Cambridge Biomedical Campus, Cambridge, UK) and our clinical research group also purchased a monoclonal antibody for Ki-67 (clone MIB-1) from Dako Denmark A/S (DK-2600 Glostrup, Denmark). Our clinical research group purchased monoclonal antibodies against CD31 (GTX130274) was purchased from GeneTex, Inc. (Irvine, CA, USA). Our clinical research group purchased the appropriate monoclonal antibodies for caveolin 1, cyclin B1, and LMP2/β1i from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). We carried out IHC experiment using the avidin–biotin complex method as described previously.

Our clinical research group incubated the tissue sections with a biotinylated secondary antibody (Dako, DK-2600 Glostrup, Denmark) conjugated with the streptavidin complex (Dako). The completed reactions were developed using 3,3'-diaminobenzidine, and our clinical research group counterstained the slides with hematoxylin. Our clinical research group used normal myometrial tissues in the specimens as positive controls. The negative controls consisted of tissue sections incubated with normal rabbit immunoglobulin (IgG) instead of the primary antibody. Shinshu University (approval no. M192) and the National Hospital Organization Kyoto Medical Center approved the experiments according to internal guidelines (approval no. KMC R02-0702). The expression of cyclin E and Ki-67/MIB was indicated by brown 3,3'-diaminobenzidine (DAB) tetrahydrochloride

staining. Our clinical research group used normal rabbit or mouse antiserum as a negative control for the primary antibody. The entire brown DAB tetrahydrochloride-stained tissue was scanned using a BZ-X800 digital microscope (Keyence, Osaka, Osaka, Japan). The expression of cyclin E and Ki-67 was indicated by brown dots.

Our clinical research group carried out IHC staining for CD31 on sections from the excised tissue. Briefly, our clinical research group incubated the tumor tissue sections with the appropriate primary antibodies at 4°C overnight. Our clinical research group used a mouse monoclonal antibody to CD31 (1:200) as the primary antibody. Our clinical research group purchased a monoclonal antibody for CD31 (clone GTX130274) from GeneTex, Inc. (Irvine, CA, USA). Following incubation with an Alexa Fluor® 488-conjugated anti-mouse IgG (1:200; Invitrogen) as second antibody, the sections were washed, cover-slipped with mounting medium and 40,6-diamidino-2-phenylindole (Vectashield; Vector Laboratories, Burlingame, CA, USA), and visualized using confocal microscopy (Leica TCS SP8, Wetzlar, Germany). The clinical research experiments with human tissues were conducted at the National Hospital Organization Kyoto Medical Center in accordance with the institutional guidelines (approval no. NHO H31-02).

2.2. Ethical approval and consent to participate

The Central Ethics Review Board of the National Hospital Organization Headquarters in Japan (Meguro, Tokyo, Japan) and Shinshu University School of Medicine (Matsumoto, Nagano, Japan) reviewed and approved this study. Ethical approval was obtained on August 17, 2019 with the code NHO H31-02. The authors attended educational lectures on medical ethics in 2020 and 2021, which were supervised by the Japanese government. The completion numbers for the authors are AP0000151756, AP0000151757, AP0000151769, and AP000351128. As this research was considered clinical research, consent to participate was required. After briefing regarding the clinical study and approval of the research contents, the participants signed an informed consent form.

Details of the materials and methods are indicated in the Supplementary Information.

3. Results

Case 1. A 53-year-old non-pregnant woman was referred to our medical facility from a nearby general medical institution for further examination due to a pelvic mass found on transabdominal ultrasonography. Transvaginal ultrasonography revealed a well-circumscribed, bright, solid mass measuring 100 × 140 mm in diameter in the corpus of the uterus. Internal blood flow on Doppler and absence of posterior echo attenuation were depicted by the mass. Pelvic MRI T1-weighted fat suppression images showed signal suppression in the same region. In the gadolinium contrast images, no contrast enhancement effect was observed. A contrast-enhanced MRI T2 image showed that the tumor wall was isointense with the myometrium, and a beak sign in the tumor capsule and flow void findings, initially thought as uterine artery branches, were observed ([Supplementary Figure 1](#)). Thus, the mass in the uterine corpus was determined to be a large, fat-containing tumor derived from the uterus. On blood tests, tumor markers and uterine cytology were negative. These findings suggest that the mass may be a lipoleiomyoma originating from the uterine corpus. In clinical studies to date, the characteristic imaging findings suggest the possibility of lipoleiomyoma preoperatively. However, in clinical practice, it is necessary to differentiate and exclude other malignant tumors such as well-differentiated liposarcoma and malignant transformation of ovarian mature cystic teratoma.

Surgical pathological findings using the excised tissue reveal multiple uterine leiomyoma-like nodules in the uterine corpus tissue. Histological findings show lipoleiomyoma, uterine leiomyoma, and hemangioma in the uterine corpus tissue ([Supplementary Figure 2](#)). There are no findings suggestive of malignancy in the endometrium, cervix, bilateral fallopian tubes, and ovary. Our molecular pathological studies to date have identified five factors (caveolin, cyclin B, cyclin E, LMP2/b1i, and Ki-67) as differentiating

markers between uterine leiomyosarcoma and other uterine mesenchymal tumors (7) (Figure 1). Therefore, the expression status of five candidate factors as biomarkers for distinguishing between uterine leiomyosarcoma and other uterine mesenchymal tumors was examined in the tumor tissue of this case and uterine leiomyosarcoma tissue.




Figure 1. Differential expression of cyclin B, cyclin E, caveolin 1, ki-67, and LMP2/β1i as potential biomarkers in the normal myometrium, uterine leiomyoma, uterine leiomyosarcoma, and uterine tumor in case 1. A. The image shows a spindle cell leiomyoma. Low-power view (10× field) shows a well-circumscribed tumor nodule in the myometrium composed of broad fascicles of spindle cells. A high-power view (40× field) shows a uterine leiomyoma (spindle cell) with bland cytological features, elongated nuclei, and fine nuclear chromatin. Immunohistochemistry (IHC) of uterine leiomyoma tissue sections was performed using monoclonal antibodies. B. The image shows uterine epithelioid leiomyosarcoma. Low-power view (10× field) shows a uterine mass and an irregular interface with the myometrium composed of round to polygonal cells with granular eosinophilic cytoplasm. Significant nuclear atypia and mitoses are evident. High-power view (40× field) shows tumor cells that are round to ovoid. The tumor cells have eosinophilic granular cytoplasm and irregularly shaped nuclei. IHC of the leiomyosarcoma tissue sections was performed using the appropriate monoclonal antibodies. C. An admixture of round, polygonal, bizarre, or spindle cells, with marked atypia, with or without giant cells and rhabdomyoblasts were seen in the uterine tumor in Case 1. Some tumors invaded the lymphatic vessels. Low-power view (10× field) shows no obvious high-grade nuclear atypia or mitotic cell proliferation, and necrosis is observed. A high-power view (40× field) showing tumor cells with significant pleomorphism, whereas some are multinucleated, and lipomyoblastic differentiation is evident. Using appropriate monoclonal antibodies, IHC of the normal the myometrium, leiomyoma, leiomyosarcoma, and uterine tumor in Case 1 was performed.

The expression of caveolin, a molecular biomarker for uterine mesenchymal tumors, was clearly confirmed in uterine leiomyoma, uterine leiomyosarcoma, and patient's uterine tumor, that is, lipoleiomyoma (Figures 1 and 2). Mild expression of cyclin B, which is considered a malignant mesenchymal tumor biomarker, was confirmed in uterine leiomyosarcoma and patient's uterine tumor (i.e., lipoleiomyoma) (Figures 1 and 2). A strong expression of cyclin E and Ki-67, which are candidate biomarkers for malignant uterine mesenchymal tumors, was confirmed in uterine leiomyosarcoma (Figures 1 and 2). Mild expression of cyclin E and Ki-67 was confirmed in the patient's uterine tumor (i.e., lipoleiomyoma) (Figures 1 and 2). Previous research reports have revealed that mice lacking LMP2/β1i, one of the immunoproteasome sub-unit factors, develop spontaneous uterine leiomyosarcoma (8). Recent reports demonstrated that in human uterine leiomyosarcoma, expression of LMP2/β1i is markedly reduced (8,9). A strong expression of LMP2/β1i was found in the patient's uterine tumor (i.e., lipoleiomyoma) similar to normal myometrium tissue and uterine leiomyoma (Figures 1 and Figure 2). Based on these results, the patient's lipoleiomyoma is probably a benign tumor; however, the possibility of malignant properties cannot be ruled out.




Figure 2. Cyclin E and Ki-67-slightly positive uterine mesenchymal tumor cells in the tumor in Case 1 compared with a normal myometrium and uterine leiomyoma. IHC of the normal myometrium, uterine leiomyoma, uterine leiomyosarcoma, and Case 1 uterine tumor (i.e., uterine lipoleiomyoma) tissues was performed using appropriate monoclonal antibodies. The tissues were randomly selected from the normal myometrium, uterine leiomyoma, uterine leiomyosarcoma, and the Case 1 uterine tumor. Under a 40× field of view, the positive rates for the five biomarkers were determined in four tissue sites under a microscope (Panthera Shimadzu Co. Ltd., Kyoto, Kyoto, Japan). The positive rates at each site for each tissue are displayed in a scatter plot. CAV1; caveolin 1, CCNB; cyclin B, CCNE; cyclin E, LMP2; LMP2/β1i. U.leiomyoma; uterine leiomyoma, U.leiomyosarcoma; uterine leiomyosarcoma, U.lipoleiomyoma; uterine lipoliomyoma.

CD31, CD34, factor VIII, D2-40, etc., are used as vascular tissue biomarkers including blood vessels in the histopathological diagnosis of vascular tumors. Of these biomarkers, CD31, because it is specifically expressed on vascular and lymphatic endothelial cells, has the highest specificity for vascular tumors (10,11). Therefore, on tissues suspected of hemangioma and uterine leiomyosarcoma, immunohistochemical staining was performed using an anti-human CD31 antibody. As a result of the IHC experiment, many CD31-positive cells were observed in the hemangioma-suspected tissue; however, only a few CD31-positive cells were found in the uterine leiomyosarcoma tissue (Figure 3A). CD31-positive cells were found to be statistically higher in suspected hemangioma tissue than in uterine leiomyosarcoma tissue (Figure 3B).




Figure 3. Significance of CD31-positive uterine hemangioma cells in Case 1. Differential expression of CD31 as a biomarker for vessel endothelial cells such as vascular endothelial cells and lymphatic endothelial cells is observed in the Case 1 hemangioma. The photograph shows the hemangioma in Case 1, uterine leiomyosarcoma, and normal myometrium. The low-power view (10× field) shows the uterine mass' irregular interface with normal myometrium, which is composed of round to polygonal cells with granular eosinophilic cytoplasm. Significant nuclear atypia and mitoses are evident. A high-power view (10× field) shows round to ovoid tumor cells. The tumor cells have a eosinophilic granular cytoplasm and irregularly shaped nuclei. IHC with the leiomyosarcoma tissue sections was performed using the appropriate monoclonal antibodies (left upper panel). Case 1 uterine tumor shows that the capillary-sized vessels are lined by plump endothelial cells. The low-power view (4× field) shows no obvious high-grade nuclear atypia or mitotic cell proliferation. The high-power view (10× field) shows that vessel endothelial cells exhibit significant pleomorphism, and some show multinucleated, vessel endothelial differentiation. Using the appropriate monoclonal antibodies, IHC was performed with the Case 1 hemangioma tissue, leiomyosarcoma tissue, and normal myometrium (upper right panel). The five tissue sites were randomly selected from normal myometrium, uterine leiomyosarcoma, and the hemangioma tissue of Case 1. In a 10× field of view, the positive rates for the biomarker were determined in three tissue sites under a microscope (Panthera Shimadzu Co. Ltd., Kyoto, Kyoto, Japan) (lower panel). The positive rates at the sites for each tissue are shown in a scatter plot. Statistical significance; $*p < 0.001$.

We examined the developing sites of lipoleiomyoma and hemangiomas in the excised tissue specimens to explore the causal relationship between concurrently occurring lipoleiomyoma and hemangiomas. The findings show no hemangioma in the lipoleiomyoma tissue, but hemangiomas were observed in the smooth muscle tissue adjacent to the lipoleiomyoma tissue (Figure 4).


Nishikawa *et al.* Figure 4

Figure 4. Identification of lipoleiomyoma and hemangioma locations by histological and pathological examination. Upper panel: block of excised tissue fixed by formalin; bottom panel: microscopic histology of each excised tissue block. Uterine lipoleiomyoma: a mixture of mature adipocytes is observed within the uterine leiomyoma. Uterine hemangioma: uterine hemangiomas consist of irregularly shaped cavernous spaces infiltrating between the myometrial fascicles. The vascular spaces are lined by flattened endothelium (positive for CD31) and distended with blood. No hemangioma was observed in the uterine lipoleiomyoma tissue; however, hemangiomas were observed in the smooth muscle tissue adjacent to the uterine lipoleiomyoma tissue.

4. Discussion

Typical leiomyomas, characterized by intersecting short fascicles of bland spindled cells with cigar-shaped nuclei, are most common; however, cellular mitotically active, myxoid, epithelioid, bizarre nuclei, and lipoleiomyoma forms also exist. Lipoleiomyoma has a variable number of mature adipocytes admixed with smooth muscle cells. First described in 1897, uterine hemangioma was an incidental discovery from an autopsy of a young woman who developed anemia and dyspnea and died 24 h after delivering twins (12). It is a rare benign vascular tumor which can cause bleeding problems in various age groups. In many cases, uterine hemangiomas cause menorrhagia and pregnancy-related complications.

A 54-year-old non-pregnant woman presented to our medical facility with significant vaginal bleeding. An outpatient MRI imaging study revealed a mass measuring 140 × 100 mm, suggestive of uterine lipoleiomyoma. After surgical treatment, the tumor was submitted for pathological examination and revealed a concurrently occurring uterine lipoleiomyoma and hemangioma. IHC experiment with appropriate antibodies for CD31 and the five candidate factors as biomarkers demonstrated differential expression of the five candidate factors and CD31 compared with other mesenchymal and leiomyomatoid

tumors. Hence, this case was established as a concurrently occurring uterine lipoleiomyoma and hemangioma. To the best of our knowledge, this is the first case of a concurrent uterine hemangioma and intramural leiomyoma (Table 1, Supplementary Table 1). Similar to normal myometrium tissue and uterine leiomyoma, a strong expression of LMP2/ β 1i was found in the patient's uterine tumor (i.e., lipoleiomyoma). Through a molecular pathological analysis using the five biomarker candidates currently under investigation, the patient's tumor was classified as a benign mesenchymal tumor.

Table 1. Differential expressions of SMA, Caveolin1, Cyclin B, Cyclin E, LMP2, NT5DC2, CD133, and Ki-67 in human uterine mesenchymal tumors and uterine LANT-like tumor.

Mesenchymal tumor types	Age years	n	Protein expression*							
			SMA	CAV1	CCNB	CCNE	LMP2	NT5DC2	CD133	Ki-67
Normal	30s-80s	74	+++	-	-	-	+++	-	-	-
Leiomyoma (LMA) (Ordinally leiomyoma) (Cellular leiomyoma)	30s-80s	40	+++	++	-/+	-/(+)	+++	-/+	-	+/-
		(30)	+++	++	-/+	-	+++	-/+		+/-
		(10)	++	++	-/+	-/(+)	++	-/+		+/-
STUMP	40s-60s	12	++	++	+	-/+	-/+	-/+	NA	+ /+++
Lipoleiomyoma	40-50s	2	NA	++	-/+	+	+++	NA	NA	++
Bizarre Leiomyoma	40s-50s	4	++	++	-/+	+	Focal+	+	NA	+
Intravenous LMA	50s	3	++	++	+	+	-	NA	++	+
Benign metastasizing	50s	1	++	++	+	++	-	NA	NA	++
Leiomyosarcoma	30s-80s	54	-/+	+	++	+++	-/+	++	++	++/+++
Rhabdomyosarcoma	10s,50s	2	NA	++	-/+	+++	+++	NA	NA	NA
U.LANT [†] -like tumour	40s	1	++	+	NA	++	-	NA	NA	-

Staining score of expression of SMA, CAV1 (Caveolin 1), CCNB (Cyclin B), CCNE (Cyclin E), LMP2 (low molecular protein 2), NT5DC2 (5'-Nucleotidase Domain Containing 2) and Ki-67 from results of IHC experiments. Protein expression; estimated-protein expressions by immunoblot analysis, immunohistochemistry (IHC) and/or RT-PCR (quantitative-PCR), -/+; partially positive (5% to 10% of cells stained), Focal+; Focal-positive (focal or sporadic staining with less than 5% of cells stained), ++; staining with 5% or more, less than 90% of cells stained, +++; diffuse-positive (homogeneous distribution with more than 90% of cells stained), -; negative (no stained cells). U.LANT-like tumour; uterine leiomyomatoid angiomatous neuroendocrine tumour-like tumour, LMP2 (ref.13,14), cyclin E(ref.13,14), caveolin1(ref.14), NT5DC2(ref.15), CD133(ref.15), Ki-67(ref.13,14). STUMP (Smooth muscle tumor of uncertain malignant potential) (ref.15,16). Cyclin E, LMP2, Caveolin1 are potential biomarker for human uterine mesenchymal tumors. LANT[†], leiomyomatoid angiomatous neuroendocrin tumour (LANT) is described as a dimorphic neurosecretory tumor with a leiomyomatous vascular component (ref.17). NA; no answer.

It is necessary to consider whether uterine-derived lipoleiomyoma and soft tissue-derived lipoleiomyoma have similar biological characteristics. Some case reports show that uterine-derived lipoleiomyoma tends to increase after menopause, and it is believed that it may have an estrogen-independent proliferative ability (18,19). Conversely, several women are diagnosed with lipoleiomyoma with irregular menstruation as the chief complaint. Previous studies using isolated human tissues have revealed that uterine mesenchymal stem cells are present between the endometrium and the smooth muscle layer junction. It is believed that reactive oxygen generated by repeated ischemia and reperfusion of blood in the uterine smooth muscle layer during the monthly menstrual cycle causes genetic abnormalities in the uterine mesenchymal stem cells, producing leiomyoma cells. Uterine mesenchymal stem cells, resulting in leiomyoma cells. In this patient, adipocytes are thought to have proliferated in the leiomyoma tissue for some reason, but the cause of uterine lipoleiomyoma has not been elucidated. The results obtained from contrast-enhanced MRI imaging provide positive clinical information for differentiation. In this patient, adipocytes are thought to have proliferated in the leiomyoma tissue for some reason; however, the cause of the uterine lipoleiomyoma has not been elucidated.

The results obtained from contrast-enhanced MRI provide positive clinical information for differentiation. In contrast, the prevalence of uterine hemangioma is high in patients with liver cirrhosis and those taking oral contraceptives. Furthermore, uterine hemangiomas are thought to develop due to abnormal secretion of estrogen. Hemangioma-like abnormality that develop during pregnancy or during oral contraceptive use resolve spontaneously 6–9 months after delivery or discontinuation of oral contraceptives. However, a significant number of patients with uterine hemangiomas present with abnormal vaginal bleeding (20), which was demonstrated in our patient. Since vaginal bleeding is difficult to control with medical management, it is important to consider the patient's intention to conceive and select the appropriate surgical treatment for uterine hemangioma.

In cases where the development of a tumor derived from the uterine smooth muscle layer is suspected based on the imaging test results and if the tumor grows rapidly or abnormal bleeding is observed, periodic follow-up and confirmation of the presence or absence of malignant findings should be repeatedly performed. The limitations of pre-operative diagnosis and the economic and psychological burden on patients and their families due to repeated tests should also be considered. In the future, more cases are necessary for data analysis, including cases where verification or follow-up was performed for uterine lipoleiomyoma and uterine hemangiomas at well-experienced medical facilities. The best treatment for hemangioma has not been established despite remarkable advances in medical technology. However, accurate clinical diagnosis is critical to prevent overtreatment of women of reproductive age. Although the prognosis is excellent after hysterectomy, further basic medical research and clinical research are needed to establish a cure for uterine hemangiomas.

5. Conclusion

Hemangiomas, or benign tumors of the blood vessels, rarely occur in the uterus. However, it can cause many clinical complications, including abdominal pain and excessive vaginal bleeding. Therefore, a close monitoring of the MRI results should be conducted by the medical staff with consideration for the patient's desire for pregnancy, including surgical treatment options for uterine hemangioma.

Author Contributions: SN, TH, and YA performed most of the clinical work and coordinated the project. TH and IK conducted the diagnostic pathological studies. SN and TH conceptualized the study and wrote the manuscript. KA, NY, and IK and carefully reviewed this manuscript and commented on the aspects of medical science. IK shared information on clinical medicine and oversaw the entirety of the study.

Funding: This clinical research was performed with research funding from the following: Japan Society for Promoting Science for TH (Grant No. 19K09840), and START-program Japan Science and Technology Agency for TH (Grant No. STSC20001), and the National Hospital Organization Multi-center clinical study for TH (Grant No. 2019-Cancer in general-02).

Acknowledgments: We thank all medical staff for providing medical care to this patient at the National Hospital Organization Kyoto Medical Center. We appreciate Crimson Interactive Japan Co., Ltd., for polishing our manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations: CD31; Cluster of Differentiation 31, DAPI; 40,6-diamidino-2-phenylindole, IHC; Immunohistochemistry, LMP2/b1i; large multifunctional peptidase 2/b1i, MRI; Magnetic Resonance Imaging, WHO; World Health Organization.

References

1. Uterine leiomyoma. Female Genital Tumours WHO Classification of Tumours, 5th ed., Vol.4. WHO Classification of Tumours Editorial Board. WORLD HEALTH ORGANIZATION. 2020; pp272-276.
2. Tamura S, Hayashi T, Tokunaga H, Yaegashi N, Abiko K, Konishi I. Oncological Properties of Intravenous Leiomyomatosis: Involvement of Mesenchymal Tumor Stem-Like Cells. *Curr Issues Mol Biol.* 2021 Sep 19;43(2):1188-1202.
3. Zaloudek CJ, Hendrickson MR, Soslow RA. Mesenchymal tumors of the uterus. In Kurman R (ed): *Blaustein's Pathology of the Female Genital Tract*, 6th ed. Springer, New York, 2010, pp453-527.

4. Stark DD, Felder RC, Wittenberg J, et al. Magnetic resonance imaging of cavernous hemangioma of the liver tissue-specific characterization. *AJR Am J Roentgenol* 1985;145:213-222.
5. Itai Y, Ohtomo K, Furui S, et al. Noninvasive diagnosis of small cavernous hemangioma of the liver advantage of MRI. *AJR Am J Roentgenol* 1985;145:1195-1199.
6. Tanimoto A, Yuasa Y, Jinzaki M, et al. Routine MR imaging protocol with breath-hold fast scans diagnostic efficacy for focal liver lesions. *Radiat Med* 2002;20:169-179.
7. Tamura S, Hayashi T, Tokunaga H, Yaegashi N, Abiko K, Konishi I. Oncological Features of Intravenous Leiomyomatosis: Involvement of Mesenchymal Tumor Stem-Like Cells. *Current Issues in Molecular Biology* 2021, 43(2), 1188-1202. <https://doi.org/10.3390/cimb43020084>
8. Hayashi T, Faustman DL. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. *Cancer Res.* 2002; 62(1): 24-27.
9. Hayashi T, Horiuchi A, Sano K, Hiraoka N, Kanai Y, Shiozawa T, Tonegawa S, Konishi I. Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma. *Protein Cell.* 2010; 1(8): 711-717. doi: 10.1007/s13238-010-0095-x.
10. Treutiger CJ, Heddini A, Fernandez V, Muller WA, Wahlgren M. PECAM-1/CD31, an endothelial receptor for binding Plasmodium falciparum-infected erythrocytes. *Nat Med.* 1997 Dec;3(12):1405-8. doi: 10.1038/nm1297-1405.
11. Giner F, Compañ A, Monteagudo C. Uterine glomeruloid hemangioma in a patient without POEMS syndrome. *Int J Surg Pathol.* 2012 Aug;20(4):407-10. doi: 10.1177/1066896911429297.
12. Johnson C, Reid-Nicholson M, Deligdisch L, Grinblat S, Natarajan S. Capillary hemangioma of the endometrium: a case report and review of the literature. *Arch Pathol Lab Med.* 2005;129(10):1326-1329. Google Scholar PubMed
13. Patent: Detection of uterine leiomyosarcoma using LMP2. Application JP2007548042A events. https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000044182
14. Hayashi, T.; Ichimura, T.; Yaegashi, N.; Shiozawa, T.; Konishi, I. Expression of CAVEOLIN 1 in uterine mesenchymal tumors: No relationship between malignancy and CAVEOLIN 1 expression. *Biochem Biophys Res Commun.* 2015; 463(4): 982-987. doi: 10.1016/j.bbrc.2015.06.046.
15. Hayashi, T.; Sano, K.; Ichimura, T.; Tonegawa, S.; Yaegashi, N.; Konishi, I. Diagnostic biomarker candidates including NT5DC2 for human uterine mesenchymal tumors. *Intl J Trend in Sci Res and Dev (IJTSRD).* 2021; 5(3): 604-606. <https://www.ijtsrd.com/papers/ijtsrd38686.pdf>
16. Smooth muscle tumor of uncertain malignant potential of the uterine corpus. *Female Genital Tumours WHO Classification of Tumours*, 5th ed., Vol.4. WHO Classification of Tumours Editorial Board. WORLD HEALTH ORGANIZATION. 2020; pp279-280.
17. Hayashi, T.; Ichimura, T.; Kasai, M.; Sano, K.; Zharhary, D.; Shiozawa, T.; Yaegashi, N.; Konishi, I. Characterization of Leiomyomatoid Angiomatous Neuroendocrine Tumour (LANT)-like Tumour in the Myometrium with Histopathological Examination. *Anticancer Res.* 2017; 37(4): 1765-1772. doi: 10.21873/anticancer.11509.
18. Oh SR, Cho YJ, Han M, Bae JW, Park JW, Rha SH. Uterine lipoleiomyoma in Peri or Postmenopausal Women. *J Menopausal Med.* 2015 Dec;21(3):165-70. doi: 10.6118/jmm.2015.21.3.165.
19. Manjunatha HK, Ramaswamy AS, Kumar BS, Kumar SP, Krishna L. Lipoleiomyoma of uterus in a postmenopausal woman. *J Midlife Health.* 2010;1:86-88.
20. Ralph C, Cuello MA, Merino PM, M FB, Astudillo K, Huete Á, García C, Pomés C. Infantile/Capillary Hemangioma of the Uterine Corpus: A Rare Cause of Abnormal Genital Bleeding. *J Pediatr Adolesc Gynecol.* 2022 Mar 15:S1083-3188(22)00175-9. doi: 10.1016/j.jpog.2022.02.001.